|
US4704362A
(en)
|
1977-11-08 |
1987-11-03 |
Genentech, Inc. |
Recombinant cloning vehicle microbial polypeptide expression
|
|
US4965188A
(en)
|
1986-08-22 |
1990-10-23 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences using a thermostable enzyme
|
|
US4683202A
(en)
|
1985-03-28 |
1987-07-28 |
Cetus Corporation |
Process for amplifying nucleic acid sequences
|
|
US4683195A
(en)
|
1986-01-30 |
1987-07-28 |
Cetus Corporation |
Process for amplifying, detecting, and/or-cloning nucleic acid sequences
|
|
DE3683980D1
(de)
|
1985-04-12 |
1992-04-02 |
Genetics Inst |
Neue prokoagulierungsproteine.
|
|
KR910006424B1
(ko)
|
1985-08-21 |
1991-08-24 |
인코텍스 비.브이 |
편성브리프(brief) 제조방법
|
|
JP2525022B2
(ja)
|
1986-01-03 |
1996-08-14 |
ジェネティックス・インスチチュ−ト・インコ−ポレ−テッド |
▲VIII▼:c因子型タンパク質の改良生産方法
|
|
US5595886A
(en)
|
1986-01-27 |
1997-01-21 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US4800159A
(en)
|
1986-02-07 |
1989-01-24 |
Cetus Corporation |
Process for amplifying, detecting, and/or cloning nucleic acid sequences
|
|
US5610278A
(en)
|
1986-06-24 |
1997-03-11 |
Novo Nordisk A/S |
Process for producing a coagulation active complex of factor VIII fragments
|
|
EP0832981A1
(en)
|
1987-02-17 |
1998-04-01 |
Pharming B.V. |
DNA sequences to target proteins to the mammary gland for efficient secretion
|
|
JP3101690B2
(ja)
|
1987-03-18 |
2000-10-23 |
エス・ビィ・2・インコーポレイテッド |
変性抗体の、または変性抗体に関する改良
|
|
US6060447A
(en)
|
1987-05-19 |
2000-05-09 |
Chiron Corporation |
Protein complexes having Factor VIII:C activity and production thereof
|
|
US5171844A
(en)
|
1987-06-12 |
1992-12-15 |
Gist-Brocades N.W. |
Proteins with factor viii activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
US6346513B1
(en)
|
1987-06-12 |
2002-02-12 |
Baxter Trading Gmbh |
Proteins with factor VIII activity: process for their preparation using genetically-engineered cells and pharmaceutical compositions containing them
|
|
DE3720246A1
(de)
|
1987-06-19 |
1988-12-29 |
Behringwerke Ag |
Faktor viii:c-aehnliches molekuel mit koagulationsaktivitaet
|
|
FR2619314B1
(fr)
|
1987-08-11 |
1990-06-15 |
Transgene Sa |
Analogue du facteur viii, procede de preparation et composition pharmaceutique le contenant
|
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
|
WO1990009800A1
(en)
|
1989-02-21 |
1990-09-07 |
Washington University |
Modified forms of reproductive hormones
|
|
US5633076A
(en)
|
1989-12-01 |
1997-05-27 |
Pharming Bv |
Method of producing a transgenic bovine or transgenic bovine embryo
|
|
SE465222C5
(sv)
|
1989-12-15 |
1998-02-10 |
Pharmacia & Upjohn Ab |
Ett rekombinant, humant faktor VIII-derivat och förfarande för dess framställning
|
|
MX9204374A
(es)
|
1991-07-25 |
1993-03-01 |
Idec Pharma Corp |
Anticuerpo recombinante y metodo para su produccion.
|
|
DK0669986T3
(da)
|
1992-11-13 |
2003-07-28 |
Idec Pharma Corp |
Fuldstændigt inaktiverede kozac-sekvenser til ekspression i pattedyr
|
|
US5736137A
(en)
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
|
SE504074C2
(sv)
|
1993-07-05 |
1996-11-04 |
Pharmacia Ab |
Proteinberedning för subkutan, intramuskulär eller intradermal administrering
|
|
US5827690A
(en)
|
1993-12-20 |
1998-10-27 |
Genzyme Transgenics Corporatiion |
Transgenic production of antibodies in milk
|
|
GB9422383D0
(en)
|
1994-11-05 |
1995-01-04 |
Wellcome Found |
Antibodies
|
|
US6818439B1
(en)
*
|
1994-12-30 |
2004-11-16 |
Chiron Corporation |
Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders
|
|
US6485726B1
(en)
|
1995-01-17 |
2002-11-26 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US6086875A
(en)
|
1995-01-17 |
2000-07-11 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of immunogens
|
|
US6030613A
(en)
|
1995-01-17 |
2000-02-29 |
The Brigham And Women's Hospital, Inc. |
Receptor specific transepithelial transport of therapeutics
|
|
US5869046A
(en)
|
1995-04-14 |
1999-02-09 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6121022A
(en)
|
1995-04-14 |
2000-09-19 |
Genentech, Inc. |
Altered polypeptides with increased half-life
|
|
US6096871A
(en)
|
1995-04-14 |
2000-08-01 |
Genentech, Inc. |
Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
|
|
US5739277A
(en)
|
1995-04-14 |
1998-04-14 |
Genentech Inc. |
Altered polypeptides with increased half-life
|
|
SE9503380D0
(sv)
|
1995-09-29 |
1995-09-29 |
Pharmacia Ab |
Protein derivatives
|
|
US6013516A
(en)
|
1995-10-06 |
2000-01-11 |
The Salk Institute For Biological Studies |
Vector and method of use for nucleic acid delivery to non-dividing cells
|
|
GB9524973D0
(en)
|
1995-12-06 |
1996-02-07 |
Lynxvale Ltd |
Viral vectors
|
|
US6458563B1
(en)
|
1996-06-26 |
2002-10-01 |
Emory University |
Modified factor VIII
|
|
AU3968897A
(en)
|
1996-08-02 |
1998-02-25 |
Bristol-Myers Squibb Company |
A method for inhibiting immunoglobulin-induced toxicity resulting from the use of immunoglobulins in therapy and in vivo diagnosis
|
|
IL128779A0
(en)
|
1996-09-06 |
2000-01-31 |
Univ Pennsylvania |
Method for recombinant adeno-associated virus-directed gene therapy
|
|
GB9621680D0
(en)
|
1996-10-17 |
1996-12-11 |
Oxford Biomedica Ltd |
Lentiviral vectors
|
|
EP1041152A1
(en)
|
1996-10-17 |
2000-10-04 |
Oxford Biomedica (UK) Limited |
Retroviral vectors
|
|
GB9622500D0
(en)
|
1996-10-29 |
1997-01-08 |
Oxford Biomedica Ltd |
Therapeutic gene
|
|
WO1998023289A1
(en)
|
1996-11-27 |
1998-06-04 |
The General Hospital Corporation |
MODULATION OF IgG BINDING TO FcRn
|
|
US6277375B1
(en)
|
1997-03-03 |
2001-08-21 |
Board Of Regents, The University Of Texas System |
Immunoglobulin-like domains with increased half-lives
|
|
CA2225189C
(en)
|
1997-03-06 |
2010-05-25 |
Queen's University At Kingston |
Canine factor viii gene, protein and methods of use
|
|
RO120148B1
(ro)
|
1997-03-14 |
2005-09-30 |
Idec Pharmaceuticals Corporation |
Sistem vector şi procedeu de inserţie a unui fragment adn, în genomul celulelor de mamifere
|
|
US6207455B1
(en)
|
1997-05-01 |
2001-03-27 |
Lung-Ji Chang |
Lentiviral vectors
|
|
WO1999003496A1
(en)
|
1997-07-21 |
1999-01-28 |
The University Of North Carolina At Chapel Hill |
Factor ix antihemophilic factor with increased clotting activity
|
|
GB9722131D0
(en)
|
1997-10-20 |
1997-12-17 |
Medical Res Council |
Method
|
|
US5994136A
(en)
|
1997-12-12 |
1999-11-30 |
Cell Genesys, Inc. |
Method and means for producing high titer, safe, recombinant lentivirus vectors
|
|
US6528624B1
(en)
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
|
US6242195B1
(en)
|
1998-04-02 |
2001-06-05 |
Genentech, Inc. |
Methods for determining binding of an analyte to a receptor
|
|
DE69937291T2
(de)
|
1998-04-02 |
2008-07-10 |
Genentech, Inc., South San Francisco |
Antikörpervarianten und fragmente davon
|
|
US6194551B1
(en)
|
1998-04-02 |
2001-02-27 |
Genentech, Inc. |
Polypeptide variants
|
|
GB9809951D0
(en)
|
1998-05-08 |
1998-07-08 |
Univ Cambridge Tech |
Binding molecules
|
|
EP1105427A2
(en)
|
1998-08-17 |
2001-06-13 |
Abgenix, Inc. |
Generation of modified molecules with increased serum half-lives
|
|
US6924365B1
(en)
|
1998-09-29 |
2005-08-02 |
Transkaryotic Therapies, Inc. |
Optimized messenger RNA
|
|
US20090017533A1
(en)
|
1998-09-29 |
2009-01-15 |
Shire Human Genetic Therapies, Inc., A Delaware Corporation |
Optimized messenger rna
|
|
US6103526A
(en)
|
1998-10-08 |
2000-08-15 |
Protein Sciences Corporation |
Spodoptera frugiperda single cell suspension cell line in serum-free media, methods of producing and using
|
|
EP1006183A1
(en)
|
1998-12-03 |
2000-06-07 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Recombinant soluble Fc receptors
|
|
US6737056B1
(en)
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
|
KR20060067983A
(ko)
|
1999-01-15 |
2006-06-20 |
제넨테크, 인크. |
효과기 기능이 변화된 폴리펩티드 변이체
|
|
ATE368122T1
(de)
|
1999-04-29 |
2007-08-15 |
Cell Genesys Inc |
Verfahren und mittel für die herstellung von sicheren rekombinanten lentiviralen vektoren mit hohem titer
|
|
CA2401327C
(en)
|
2000-03-03 |
2014-05-06 |
Valentis, Inc. |
Nucleic acid formulations comprising poly-amino acids for gene delivery and methods of use
|
|
ES2529300T3
(es)
|
2000-04-12 |
2015-02-18 |
Novozymes Biopharma Dk A/S |
Proteínas de fusión de albúmina
|
|
WO2002040544A2
(en)
|
2000-11-14 |
2002-05-23 |
Board Of Regents, University Of Texas Systems |
Mutant human factor ix with an increased resistance to inhibition by heparin
|
|
GB0029407D0
(en)
|
2000-12-01 |
2001-01-17 |
Affitech As |
Product
|
|
EP2357187A1
(en)
|
2000-12-12 |
2011-08-17 |
MedImmune, LLC |
Molecules with extended half-lives, compositions and uses thereof
|
|
US20020159978A1
(en)
|
2001-02-06 |
2002-10-31 |
James Allen |
Muscle-directed gene transfer by use of recombinant AAV-1 and AAV-6 virions
|
|
US6888319B2
(en)
|
2001-03-01 |
2005-05-03 |
Palomar Medical Technologies, Inc. |
Flashlamp drive circuit
|
|
CA2440582A1
(en)
|
2001-03-09 |
2002-10-03 |
Dyax Corp. |
Serum albumin binding moieties
|
|
US20040106794A1
(en)
|
2001-04-16 |
2004-06-03 |
Schering Corporation |
3,4-Di-substituted cyclobutene-1,2-diones as CXC-chemokine receptor ligands
|
|
EP1395293B1
(en)
|
2001-05-14 |
2009-07-22 |
Gbp Ip, Llc |
Lentiviral vectors encoding clotting factors for gene therapy
|
|
EP1427820A2
(en)
|
2001-09-04 |
2004-06-16 |
MERCK PATENT GmbH |
Modified factor ix
|
|
CA2467959C
(en)
|
2001-11-09 |
2009-03-10 |
Robert M. Kotin |
Production of adeno-associated virus in insect cells
|
|
NZ618298A
(en)
|
2001-11-13 |
2015-04-24 |
Univ Pennsylvania |
A method of detecting and/or identifying adeno-associated virus (aav) sequences and isolating novel sequences identified thereby
|
|
JP4810062B2
(ja)
|
2001-12-17 |
2011-11-09 |
ザ・トラステイーズ・オブ・ザ・ユニバーシテイ・オブ・ペンシルベニア |
アデノ随伴ウイルス(aav)血清型8の配列
|
|
WO2003060071A2
(en)
|
2001-12-21 |
2003-07-24 |
Human Genome Sciences, Inc. |
Albumin fusion proteins
|
|
US20080194481A1
(en)
|
2001-12-21 |
2008-08-14 |
Human Genome Sciences, Inc. |
Albumin Fusion Proteins
|
|
KR101271635B1
(ko)
|
2001-12-21 |
2013-06-12 |
휴먼 게놈 사이언시즈, 인코포레이티드 |
알부민 융합 단백질
|
|
US6899917B2
(en)
|
2001-12-27 |
2005-05-31 |
3M Innovative Properties Company |
Powdered epoxy composition
|
|
US20040002587A1
(en)
|
2002-02-20 |
2004-01-01 |
Watkins Jeffry D. |
Fc region variants
|
|
US7317091B2
(en)
|
2002-03-01 |
2008-01-08 |
Xencor, Inc. |
Optimized Fc variants
|
|
JP2006502091A
(ja)
|
2002-03-01 |
2006-01-19 |
イミューノメディクス、インコーポレイテッド |
クリアランス速度を高めるための二重特異性抗体点変異
|
|
US20040132101A1
(en)
|
2002-09-27 |
2004-07-08 |
Xencor |
Optimized Fc variants and methods for their generation
|
|
AU2002316574B2
(en)
|
2002-03-15 |
2008-05-01 |
Brandeis University |
Central airway administration for systemic delivery of therapeutics
|
|
US6615782B1
(en)
|
2002-04-12 |
2003-09-09 |
Delphi Technologies, Inc. |
Two-step finger follower rocker arm
|
|
US7211558B2
(en)
|
2002-05-22 |
2007-05-01 |
The Children's Hospital Of Philadelphia |
Compositions and methods for the treatment of hemophilia A
|
|
DK1534335T4
(en)
|
2002-08-14 |
2015-10-05 |
Macrogenics Inc |
FCGAMMARIIB-SPECIFIC ANTIBODIES AND PROCEDURES FOR USE THEREOF
|
|
EP3321282A1
(en)
|
2002-09-27 |
2018-05-16 |
Xencor, Inc. |
Optimized fc variants and methods for their generation
|
|
CA2502904C
(en)
|
2002-10-15 |
2013-05-28 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
GB2395337B
(en)
|
2002-11-14 |
2005-12-28 |
Gary Michael Wilson |
Warning Unit
|
|
WO2004063351A2
(en)
|
2003-01-09 |
2004-07-29 |
Macrogenics, Inc. |
IDENTIFICATION AND ENGINEERING OF ANTIBODIES WITH VARIANT Fc REGIONS AND METHODS OF USING SAME
|
|
US7041635B2
(en)
|
2003-01-28 |
2006-05-09 |
In2Gen Co., Ltd. |
Factor VIII polypeptide
|
|
US20090010920A1
(en)
|
2003-03-03 |
2009-01-08 |
Xencor, Inc. |
Fc Variants Having Decreased Affinity for FcyRIIb
|
|
US8388955B2
(en)
|
2003-03-03 |
2013-03-05 |
Xencor, Inc. |
Fc variants
|
|
US9715692B1
(en)
|
2003-04-11 |
2017-07-25 |
Facebook, Inc. |
System for managing bids for pay-per-click search engines
|
|
ATE381620T1
(de)
|
2003-04-24 |
2008-01-15 |
San Raffaele Centro Fond |
Synthetische bidirektionale promotoren und deren verwendungen
|
|
TWI353991B
(en)
|
2003-05-06 |
2011-12-11 |
Syntonix Pharmaceuticals Inc |
Immunoglobulin chimeric monomer-dimer hybrids
|
|
CA2533701A1
(en)
|
2003-07-31 |
2005-02-17 |
Isis Pharmaceuticals, Inc. |
Oligomeric compounds and compositions for use in modulation of small non-coding rnas
|
|
GB0324368D0
(en)
|
2003-10-17 |
2003-11-19 |
Univ Cambridge Tech |
Polypeptides including modified constant regions
|
|
GB0325379D0
(en)
|
2003-10-30 |
2003-12-03 |
Oxford Biomedica Ltd |
Vectors
|
|
WO2005077981A2
(en)
|
2003-12-22 |
2005-08-25 |
Xencor, Inc. |
Fc POLYPEPTIDES WITH NOVEL Fc LIGAND BINDING SITES
|
|
EP1706424B1
(en)
|
2004-01-12 |
2009-07-22 |
Applied Molecular Evolution, Inc. |
Fc region variants
|
|
WO2005092925A2
(en)
|
2004-03-24 |
2005-10-06 |
Xencor, Inc. |
Immunoglobulin variants outside the fc region
|
|
WO2005123780A2
(en)
|
2004-04-09 |
2005-12-29 |
Protein Design Labs, Inc. |
Alteration of fcrn binding affinities or serum half-lives of antibodies by mutagenesis
|
|
CA2572467A1
(en)
|
2004-07-01 |
2006-01-19 |
Virxsys Corporation |
Vector packaging cell line
|
|
WO2006085967A2
(en)
|
2004-07-09 |
2006-08-17 |
Xencor, Inc. |
OPTIMIZED ANTI-CD20 MONOCONAL ANTIBODIES HAVING Fc VARIANTS
|
|
PL2471813T3
(pl)
|
2004-07-15 |
2015-09-30 |
Xencor Inc |
Zoptymalizowane warianty Fc
|
|
EP2438931B1
(en)
|
2004-09-22 |
2013-11-13 |
St. Jude Children's Research Hospital |
Improved expression of factor IX in gene therapy vectors
|
|
WO2006047350A2
(en)
|
2004-10-21 |
2006-05-04 |
Xencor, Inc. |
IgG IMMUNOGLOBULIN VARIANTS WITH OPTIMIZED EFFECTOR FUNCTION
|
|
PL2002003T3
(pl)
|
2005-05-27 |
2016-06-30 |
Ospedale San Raffaele Srl |
Wektor genetyczny zawierający mi-RNA
|
|
WO2007004670A1
(ja)
|
2005-07-05 |
2007-01-11 |
Kaneka Corporation |
メタクリル系樹脂組成物
|
|
MX2008001865A
(es)
|
2005-08-12 |
2008-04-15 |
Human Genome Sciences Inc |
Proteinas de fusion de albumina.
|
|
PT3272872T
(pt)
|
2005-10-20 |
2020-06-26 |
Uniqure Ip Bv |
Vetores aav melhorados produzidos em células de insetos
|
|
US8048848B2
(en)
|
2006-02-03 |
2011-11-01 |
Prolor Biotech Ltd. |
Long-acting interferons and derivatives thereof and methods thereof
|
|
US8476234B2
(en)
|
2006-02-03 |
2013-07-02 |
Prolor Biotech Inc. |
Long-acting coagulation factors and methods of producing same
|
|
WO2007104146A1
(en)
|
2006-03-13 |
2007-09-20 |
Tir Technology Lp |
Adaptive control apparatus and method for a solid-state lighting system
|
|
TW200804416A
(en)
|
2006-06-19 |
2008-01-16 |
Nautilus Technology Llc |
Modified coagulation factor IX polypeptides and use thereof for treatment
|
|
US8198421B2
(en)
|
2006-06-19 |
2012-06-12 |
Asklepios Biopharmaceutical, Inc. |
Modified factor VIII and factor IX genes and vectors for gene therapy
|
|
AU2007261806B2
(en)
|
2006-06-21 |
2013-08-15 |
Uniqure Ip B.V. |
Vectors with modified initiation codon for the translation of AAV-Rep78 useful for production of AAV in insect cells
|
|
GB0614780D0
(en)
|
2006-07-25 |
2006-09-06 |
Ucb Sa |
Biological products
|
|
JP2010503396A
(ja)
|
2006-09-14 |
2010-02-04 |
ヒューマン ジノーム サイエンシーズ, インコーポレイテッド |
アルブミン融合タンパク質
|
|
US8167585B2
(en)
|
2006-09-28 |
2012-05-01 |
Siemens Industry, Inc. |
Devices and/or systems for mounting an auxiliary blower
|
|
US7700734B2
(en)
|
2007-01-09 |
2010-04-20 |
Shu-Wha Lin |
Recombinant human factor IX and use thereof
|
|
US20080260738A1
(en)
|
2007-04-18 |
2008-10-23 |
Moore Margaret D |
Single chain fc, methods of making and methods of treatment
|
|
NZ581395A
(en)
|
2007-05-14 |
2012-08-31 |
Biogen Idec Inc |
Single-chain fc (scfc) regions, binding polypeptides comprising same, and methods related thereto
|
|
KR101631323B1
(ko)
|
2007-06-21 |
2016-06-17 |
엑스엘-프로테인 게엠베하 |
증가된 생체내 및/또는 시험관내 안정성을 갖는 생물학적 활성 단백질
|
|
CN102026653B
(zh)
|
2007-10-15 |
2014-06-18 |
北卡罗来纳-查佩尔山大学 |
半衰期延长的人因子ⅸ变体
|
|
WO2009075772A1
(en)
|
2007-12-06 |
2009-06-18 |
Wyeth |
Crystal structure of human factor viii and uses thereof
|
|
WO2009137254A2
(en)
|
2008-04-16 |
2009-11-12 |
Bayer Healthcare Llc |
Modified factor ix polypeptides and uses thereof
|
|
JP2011517950A
(ja)
|
2008-04-16 |
2011-06-23 |
バイエル・ヘルスケア・エルエルシー |
第ix因子の部位特異的修飾
|
|
WO2009130198A2
(en)
|
2008-04-21 |
2009-10-29 |
Novo Nordisk A/S |
Hyperglycosylated human coagulation factor ix
|
|
US10273502B2
(en)
|
2008-06-18 |
2019-04-30 |
Oxford Biomedica (Uk) Limited |
Virus purification
|
|
WO2009153563A1
(en)
|
2008-06-18 |
2009-12-23 |
Oxford Biomedica (Uk) Limited |
Virus purification
|
|
EP2149603A1
(en)
|
2008-07-28 |
2010-02-03 |
DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH |
Factor IX variants with clotting activity in absence of their cofactor and their use for treating bleeding disorders
|
|
EP2337849B1
(en)
|
2008-09-15 |
2018-06-13 |
uniQure biopharma B.V. |
Factor ix polypeptide mutant, its uses and a method for its production
|
|
US9938540B2
(en)
|
2008-11-12 |
2018-04-10 |
Ospedale San Raffaele S.R.L. |
Gene vector for inducing transgene-specific immune tolerance
|
|
US8703717B2
(en)
|
2009-02-03 |
2014-04-22 |
Amunix Operating Inc. |
Growth hormone polypeptides and methods of making and using same
|
|
WO2010091122A1
(en)
|
2009-02-03 |
2010-08-12 |
Amunix, Inc. |
Extended recombinant polypeptides and compositions comprising same
|
|
US8680050B2
(en)
|
2009-02-03 |
2014-03-25 |
Amunix Operating Inc. |
Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
|
|
US9050269B2
(en)
|
2009-03-10 |
2015-06-09 |
The Trustees Of The University Of Pennsylvania |
Protection of virus particles from phagocytosis by expression of CD47
|
|
ES2427627T3
(es)
|
2009-04-06 |
2013-10-31 |
Novo Nordisk A/S |
Entrega dirigida de proteínas de Factor VIII a plaquetas
|
|
ES2786039T3
(es)
|
2009-04-30 |
2020-10-08 |
Ospedale San Raffaele Srl |
Vector génico
|
|
US8734809B2
(en)
|
2009-05-28 |
2014-05-27 |
University Of Massachusetts |
AAV's and uses thereof
|
|
EP2437786B1
(en)
|
2009-06-01 |
2016-05-18 |
Yeda Research and Development Co. Ltd. |
Prodrugs containing albumin binding probe
|
|
NZ621868A
(en)
|
2009-06-08 |
2015-10-30 |
Amunix Operating Inc |
Growth hormone polypeptides and methods of making and using same
|
|
EP2440228B8
(en)
|
2009-06-08 |
2023-02-22 |
Amunix Operating Inc. |
Glucose-regulating polypeptides and methods of making and using same
|
|
GB0911870D0
(en)
|
2009-07-08 |
2009-08-19 |
Ucl Business Plc |
Optimised coding sequence and promoter
|
|
EP2470559B1
(en)
|
2009-08-24 |
2017-03-22 |
Amunix Operating Inc. |
Coagulation factor ix compositions and methods of making and using same
|
|
WO2011028344A2
(en)
|
2009-08-25 |
2011-03-10 |
Amunix Operating Inc. |
Interleukin-1 receptor antagonist compositions and methods of making and using same
|
|
MX2012003175A
(es)
|
2009-09-18 |
2012-04-11 |
Micromet Ag |
Regimen de dosificacion para administrar un anticuerpo bi-especifico epcamxcd3.
|
|
US8326547B2
(en)
|
2009-10-07 |
2012-12-04 |
Nanjingjinsirui Science & Technology Biology Corp. |
Method of sequence optimization for improved recombinant protein expression using a particle swarm optimization algorithm
|
|
SI2506868T1
(en)
|
2009-12-06 |
2018-04-30 |
Bioverativ Therapeutics Inc. |
HYPER AND HYBRID POLYPETTIDES FACTOR VIII-FC AND METHODS FOR THEIR USE
|
|
MX2012009809A
(es)
|
2010-02-23 |
2012-11-23 |
Sanofi Sa |
Anticuerpos anti - integrina alfa2 y sus usos.
|
|
JP5963743B2
(ja)
|
2010-04-23 |
2016-08-03 |
ユニバーシティ オブ マサチューセッツ |
Cnsターゲティングaavベクターおよびその使用方法
|
|
EA028067B1
(ru)
|
2010-07-09 |
2017-10-31 |
Байоджен Хемофилия Инк. |
Способы контроля или предотвращения кровотечения или эпизодов кровотечения
|
|
EP3508573A1
(en)
|
2010-07-09 |
2019-07-10 |
Bioverativ Therapeutics Inc. |
Systems for factor viii processing and methods thereof
|
|
DK2591099T3
(da)
|
2010-07-09 |
2021-02-15 |
Bioverativ Therapeutics Inc |
Kimære koagulationsfaktorer
|
|
US20130017997A1
(en)
|
2010-08-19 |
2013-01-17 |
Amunix Operating Inc. |
Factor VIII Compositions and Methods of Making and Using Same
|
|
EP2714909A4
(en)
|
2011-06-03 |
2014-12-17 |
Univ Michigan |
PROCESS FOR THE PREPARATION OF FACTOR VIII PROTEINS BY RECOMBINATION PROCEDURES
|
|
LT2729161T
(lt)
|
2011-07-08 |
2019-04-10 |
Bioverativ Therapeutics Inc. |
Faktoriaus viii chimeriniai ir hibridiniai polipeptidai ir jų panaudojimo būdai
|
|
WO2013093760A2
(en)
|
2011-12-19 |
2013-06-27 |
Grifols, S.A. |
Compositions, methods, and kits for preparing sialylated recombinant proteins
|
|
RS59670B1
(sr)
|
2012-01-12 |
2020-01-31 |
Bioverativ Therapeutics Inc |
Himerni polipeptidi faktora viii i njihove upotrebe
|
|
PT2814840T
(pt)
|
2012-02-15 |
2020-01-28 |
Bioverativ Therapeutics Inc |
Composições de fator viii e métodos de produção e utilização das mesmas
|
|
HUE043537T2
(hu)
|
2012-02-15 |
2019-08-28 |
Bioverativ Therapeutics Inc |
Rekombináns VIII faktor fehérjék
|
|
CN103316356B
(zh)
|
2012-03-22 |
2016-08-17 |
北京三诺佳邑生物技术有限责任公司 |
一种重组慢病毒载体制剂
|
|
WO2013151663A1
(en)
|
2012-04-02 |
2013-10-10 |
modeRNA Therapeutics |
Modified polynucleotides for the production of membrane proteins
|
|
HK1207591A1
(en)
|
2012-06-08 |
2016-02-05 |
Biogen Ma Inc. |
Chimeric clotting factors
|
|
RS59876B1
(sr)
|
2012-07-11 |
2020-03-31 |
Bioverativ Therapeutics Inc |
Kompleks faktora viii sa xten i proteinom fon vilebrandovog faktora, i njihova primena
|
|
RU2500816C1
(ru)
|
2012-07-19 |
2013-12-10 |
Общество с ограниченной ответственностью "Международный биотехнологический центр "Генериум" ("МБЦ "Генериум") |
РЕКОМБИНАНТНАЯ ПЛАЗМИДНАЯ ДНК рАК380, КОДИРУЮЩАЯ ПОЛИПЕПТИД РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА, ЛИНИЯ КЛЕТОК Cricetulus griseus CHO 1E6 - ПРОДУЦЕНТ РЕКОМБИНАНТНОГО ФАКТОРА IХ СВЕРТЫВАЕМОСТИ КРОВИ ЧЕЛОВЕКА И СПОСОБ ПОЛУЧЕНИЯ ПОЛИПЕПТИДА, ОБЛАДАЮЩЕГО АКТИВНОСТЬЮ РЕКОМБИНАНТНОГО ФАКТОРА IХ
|
|
DK2911687T3
(da)
*
|
2012-10-26 |
2019-05-13 |
Univ Brussel Vrije |
Vektor til levermålrettet genterapi af hæmofili og fremgangsmåder og anvendelse deraf
|
|
HUE063051T2
(hu)
|
2013-02-15 |
2023-12-28 |
Bioverativ Therapeutics Inc |
Optimalizált VIII. faktor gén
|
|
TW202003554A
(zh)
|
2013-08-14 |
2020-01-16 |
美商百歐維拉提夫治療公司 |
因子viii-xten融合物及其用途
|
|
EP2881463A1
(en)
|
2013-12-09 |
2015-06-10 |
DRK-Blutspendedienst Baden-Württemberg-Hessen gGmbH |
Factor IX variants with clotting activity in absence of their cofactor and/or with increased F.IX clotting activity and their use for treating bleeding disorders
|
|
EP3091997B1
(en)
|
2014-01-10 |
2022-07-06 |
Bioverativ Therapeutics Inc. |
Factor viii chimeric proteins and uses thereof
|
|
WO2016004113A1
(en)
*
|
2014-06-30 |
2016-01-07 |
Biogen Ma Inc. |
Optimized factor ix gene
|
|
GB201412494D0
(en)
|
2014-07-14 |
2014-08-27 |
Ospedale San Raffaele And Fond Telethon |
Vector production
|
|
TWI707951B
(zh)
|
2015-04-08 |
2020-10-21 |
美商健臻公司 |
過大腺相關載體之製造
|
|
ES2763551T3
(es)
|
2015-04-16 |
2020-05-29 |
Univ Emory |
Promotores y vectores recombinantes para la expresión de proteínas en el hígado y uso de los mismos
|
|
JP6909203B2
(ja)
|
2015-08-03 |
2021-07-28 |
バイオベラティブ セラピューティクス インコーポレイテッド |
第ix因子融合タンパク質及びそれらの製造方法及び使用方法
|
|
EP3907283A3
(en)
|
2015-11-19 |
2022-01-26 |
Novartis AG |
Buffers for stabilization of lentiviral preparations
|
|
ES2926585T3
(es)
|
2016-02-01 |
2022-10-27 |
Bioverativ Therapeutics Inc |
Genes de Factor VIII optimizados
|
|
JP2021512090A
(ja)
|
2018-01-30 |
2021-05-13 |
モデルナティーエックス, インコーポレイテッド |
免疫細胞に薬剤を送達するための組成物及び方法
|
|
CA3090136A1
(en)
|
2018-02-01 |
2019-08-08 |
Bioverativ Therapeutics, Inc. |
Use of lentiviral vectors expressing factor viii
|
|
WO2020113197A1
(en)
|
2018-11-30 |
2020-06-04 |
Vaccine Stabilization Institute |
Viral formulations containing amino acids
|
|
TW202039855A
(zh)
|
2018-12-06 |
2020-11-01 |
美商百歐維拉提夫治療公司 |
表現因子ix之慢病毒載體的用途
|
|
TW202126284A
(zh)
|
2019-09-30 |
2021-07-16 |
美商百歐維拉提夫治療公司 |
慢病毒載體配製物
|
|
BR112022026127A2
(pt)
|
2020-06-24 |
2023-01-17 |
Bioverativ Therapeutics Inc |
Métodos para remoção de fator viii livre de preparações de vetores lentivirais modificados para expressar referida proteína
|
|
JP2023538666A
(ja)
|
2020-08-23 |
2023-09-08 |
バイオベラティブ セラピューティクス インコーポレイテッド |
閉端DNA(ceDNA)の改善された製造のための改変バキュロウイルス系
|